Cigna (CI)

NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-10-15

$302.30+1.17%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Cigna’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Oct 4, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.0%

+10% or more+5%0%−5%−10% or less

33.48 → 33.48 EPS · FY ending Dec 31, 2027 · 15 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 15 to 15; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted income from operations per share	Cigna's adjusted income from operations is on track to exceed $30.45 per share.	Intact	falls below 30.45 per share	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 7 of last 7 quarters. Adjusted income from operations per share guidance increased from at least $29.50 in 2024-Q4 to at least $30.45 in 2026-Q2. Actual adjusted income from operations was $2.1 billion or $7.78 per share in 2026-Q2, showing delivering trajectory consistent with management's stated growth priority. Delivery assessment Oct 15, 2026
Total revenue	A primary condition in Cigna's published investment case. The stated target is >=4.5 billion.	Intact	falls below 4.5 billion	Revenue: $71.668B FY2026-Q2; GAAP. Published target: >=4.5 billion. Target period is not explicitly aligned with this observation. Source published Jul 30, 202671,668,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cf00f644-b451-4d69-a826-296191276b61. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
SG&A expense ratio	The company is also focused on improving its operating efficiency, as seen in the reduction of its SG&A expense ratio to 4.8%.	Intact	exceeds 4.8%	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. SG&A expense ratio improved from 5.1% in 2025-Q2 to 4.8% in 2026-Q2, reflecting improved operating efficiency. The consistent focus on expense management is delivering measurable cost discipline. Delivery assessment Oct 15, 2026

Stored thesis · Oct 4, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$33.48

$33.48 → $33.48 · observed estimates

FY2027 revenue$299.90B

$296.83B → $299.90B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$33.48	$296,834,525,940	24 / 14
2026-07-25	$33.48	$296,834,525,940	24 / 14
2026-07-26	$33.48	$296,834,525,940	24 / 14
2026-07-27	$33.48	$297,064,357,540	24 / 15
2026-07-28	$33.48	$297,064,357,540	24 / 15
2026-07-29	$33.48	$297,064,357,540	24 / 15
2026-07-30	$33.48	$297,064,357,540	24 / 15
2026-07-31	$33.49	$297,263,757,540	24 / 15
2026-08-01	$33.49	$297,263,757,540	24 / 15
2026-08-02	$33.51	$298,231,667,170	24 / 15
2026-08-03	$33.51	$298,231,667,170	24 / 15
2026-08-04	$33.51	$298,231,667,170	24 / 15
2026-08-05	$33.47	$298,715,556,510	24 / 15
2026-08-06	$33.50	$298,950,152,442	15 / 12
2026-08-07	$33.50	$298,950,152,442	15 / 12
2026-08-08	$33.47	$298,715,556,510	24 / 15
2026-08-09	$33.47	$298,715,556,510	24 / 15
2026-08-10	$33.50	$298,950,152,442	15 / 12
2026-08-11	$33.50	$298,950,152,442	15 / 12
2026-08-12	$33.50	$298,950,152,442	15 / 12
2026-08-13	$33.50	$298,950,152,442	15 / 12
2026-08-14	$33.50	$298,950,152,442	15 / 12
2026-08-15	$33.50	$298,950,152,442	15 / 12
2026-08-16	$33.50	$298,950,152,442	15 / 12
2026-08-17	$33.50	$298,950,152,442	15 / 12
2026-08-18	$33.50	$298,950,152,442	15 / 12
2026-08-19	$33.50	$298,950,152,442	15 / 12
2026-08-20	$33.47	$299,614,848,410	15 / 12
2026-08-21	$33.47	$299,614,848,410	15 / 12
2026-08-22	$33.47	$299,614,848,410	15 / 12
2026-08-23	$33.47	$299,614,848,410	15 / 12
2026-08-24	$33.47	$299,614,848,410	15 / 12
2026-08-25	$33.47	$299,614,848,410	15 / 12
2026-08-26	$33.47	$299,614,848,410	15 / 12
2026-08-27	$33.47	$299,614,848,410	15 / 12
2026-08-28	$33.47	$299,614,848,410	15 / 12
2026-08-29	$33.48	$299,597,634,124	15 / 12
2026-08-30	$33.48	$299,597,634,124	15 / 12
2026-08-31	$33.48	$299,597,634,124	15 / 12
2026-09-01	$33.48	$299,597,634,124	15 / 12
2026-09-02	$33.48	$299,597,634,124	15 / 12
2026-09-03	$33.48	$299,597,634,124	15 / 12
2026-09-04	$33.48	$299,597,634,124	15 / 12
2026-09-05	$33.48	$299,597,634,124	15 / 12
2026-09-06	$33.48	$299,597,634,124	15 / 12
2026-09-07	$33.48	$299,597,634,124	15 / 12
2026-09-08	$33.48	$299,597,634,124	15 / 12
2026-09-09	$33.48	$299,597,634,124	15 / 12
2026-09-10	$33.48	$299,291,125,183	15 / 12
2026-09-11	$33.48	$299,291,125,183	15 / 12
2026-09-12	$33.48	$299,291,125,183	15 / 13
2026-09-13	$33.48	$299,291,125,183	15 / 13
2026-09-14	$33.48	$299,291,125,183	15 / 13
2026-09-15	$33.48	$299,291,125,183	15 / 13
2026-09-16	$33.48	$299,291,125,183	15 / 13
2026-09-17	$33.45	$299,291,125,183	15 / 13
2026-09-18	$33.45	$299,291,125,183	15 / 13
2026-09-19	$33.45	$299,291,125,183	15 / 13
2026-09-20	$33.45	$299,291,125,183	15 / 13
2026-09-21	$33.45	$299,291,125,183	15 / 13
2026-09-22	$33.45	$299,291,125,183	15 / 13
2026-09-23	$33.45	$299,291,125,183	15 / 13
2026-09-24	$33.45	$299,291,125,183	15 / 12
2026-09-25	$33.45	$299,400,617,359	15 / 13
2026-09-26	$33.43	$299,586,910,330	15 / 13
2026-09-27	$33.43	$299,586,910,330	15 / 13
2026-09-28	$33.43	$299,586,910,330	15 / 13
2026-09-29	$33.43	$299,586,910,330	15 / 13
2026-09-30	$33.43	$299,586,910,330	15 / 13
2026-10-01	$33.43	$299,587,629,080	15 / 13
2026-10-02	$33.42	$299,416,785,330	15 / 13
2026-10-03	$33.47	$299,732,403,793	15 / 13
2026-10-04	$33.47	$299,732,403,793	15 / 13
2026-10-05	$33.47	$299,732,403,793	15 / 13
2026-10-06	$33.47	$299,732,403,793	15 / 13
2026-10-07	$33.47	$299,724,778,793	15 / 13
2026-10-08	$33.48	$299,895,066,293	15 / 13
2026-10-09	$33.48	$299,895,066,293	15 / 13
2026-10-10	$33.48	$299,895,066,293	15 / 13
2026-10-11	$33.48	$299,895,066,293	15 / 13
2026-10-12	$33.48	$299,895,066,293	15 / 13
2026-10-13	$33.48	$299,895,066,293	15 / 13
2026-10-14	$33.48	$299,895,066,293	15 / 13
2026-10-15	$33.48	$299,895,066,293	15 / 13

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	22	4
2026-06-01	20	4
2026-07-01	20	4
2026-08-01	21	5
2026-09-01	19	6
2026-10-01	18	6

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 18 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades2 maintains

Recent actions · Sep 16–Oct 15 · 2 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Piper SandlerOct 2 · prior Oct 2

$370.00 → $387.00+4.6%

$0$212.85$425.70

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted income from operations per shareDirect metric needs a verified mapping
Total revenueRevenue: $71.668B
SG&A expense ratioDirect metric needs a verified mapping

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.1%Typical daily move · historical

Downside history

-20.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Cigna outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on steady income growth. The current thesis state is stable, supported by recent strong financial performance and management's commitment to key priorities.

What's priced into Cigna

The market seems to price Cigna as a cheap option compared to its peers, with an expectations gap indicating that investors may not fully anticipate the company's potential for income growth. The valuation is justified, suggesting that the current pricing reflects a reasonable assessment of the company's fundamentals.

What the fundamentals likely do

Management is on track to increase adjusted income from operations, which has been a consistent priority. However, there is mixed delivery in growing Evernorth Health Services adjusted income, indicating some challenges ahead.

What Cigna hinges on

The thesis hinges on maintaining operational momentum and avoiding negative guidance changes, which could harm credibility. Additionally, the performance of sector bellwethers like UNH and CVS will be crucial in shaping market sentiment.